Top MarketRank™ StocksTop MarketRank™Most-Downgraded StocksMost-DowngradedNASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $69.55 -0.35 (-0.50%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About DexCom Stock (NASDAQ:DXCM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DexCom alerts:Sign Up Key Stats Today's Range$69.20▼$70.4050-Day Range$65.68▼$77.6952-Week Range$62.34▼$142.00Volume3.80 million shsAverage Volume3.83 million shsMarket Capitalization$27.66 billionP/E Ratio42.93Dividend YieldN/APrice Target$110.73Consensus RatingModerate Buy Company OverviewDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More… Here’s how to start a “Weekend Side Hustle” from your sofa (Ad)Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand. And that’s how you can kickstart your very own “Weekend Side Hustle!” Now that you know that…Let me show you how I target extra income as early as THIS weekend! DexCom Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks99th Percentile Overall ScoreDXCM MarketRank™: DexCom scored higher than 99% of companies evaluated by MarketBeat, and ranked 9th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth18.93% Earnings GrowthEarnings for DexCom are expected to grow by 18.93% in the coming year, from $1.69 to $2.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 42.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.32.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 42.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.15.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.16. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 13.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.40% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently increased by 11.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.76 Percentage of Shares Shorted2.40% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently increased by 11.70%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.13 News SentimentDexCom has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 40 news articles for DexCom this week, compared to 19 articles on an average week.Search InterestOnly 16 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat Follows8 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $126,390.00 in company stock.Percentage Held by InsidersOnly 0.30% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address DXCM Stock News HeadlinesThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DexCom, Inc. (DXCM)October 17 at 6:01 PM | tmcnet.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – DXCMOctober 17 at 3:11 PM | globenewswire.comThis man beat out 16,000 stock pickers to earn the #1 spotThere are very few people in this world who are considered “the best” in their field. There are guys like Michael Jordan who is considered the best basketball player of all time… Or Warren Buffet who is considered the best Investor of all time… But we’ve just met a man who might be the best stock picker of all time… Right now, as we speak, he is currently ranked the #1 stock picker in North America.October 17, 2024 | DTI (Ad)DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud LawsuitOctober 17 at 2:02 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. - DXCMOctober 17 at 1:41 PM | prnewswire.comDXCM Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action LawsuitOctober 17 at 10:00 AM | prnewswire.comDXCM FRAUD NOTICE: Lost Money on Your DexCom, Inc. Securities? Contact BFA Law by October 21 Deadline in Securities Fraud Class Action (Nasdaq:DXCM)October 17 at 6:06 AM | globenewswire.comThe Gross Law Firm Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming DeadlineOctober 17 at 5:45 AM | prnewswire.comSee More Headlines DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $124.09 on January 1st, 2024. Since then, DXCM stock has decreased by 44.0% and is now trading at $69.55. View the best growth stocks for 2024 here. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Thursday, July, 25th. The medical device company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm's revenue for the quarter was up 15.3% on a year-over-year basis. Read the conference call transcript. When did DexCom's stock split? Shares of DexCom split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were distributed to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Does DexCom have any subsidiaries? DexCom subsidiaries include TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and others. Who are DexCom's major shareholders? Top institutional investors of DexCom include Factory Mutual Insurance Co. (0.10%), Covea Finance (0.06%), Swedbank AB (0.05%) and Handelsbanken Fonder AB (0.04%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Steven Robert Pacelli, Jereme M Sylvain, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Bridgette P Heller, Chad Patterson, Barbara Kahn, Richard Alexander Collins, Mark G Foletta and Nicholas Augustinos. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ). Company Calendar Last Earnings7/25/2024Today10/17/2024Next Earnings (Confirmed)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees9,600Year Founded1999Price Target and Rating Average Stock Price Target$110.73 High Stock Price Target$161.00 Low Stock Price Target$75.00 Potential Upside/Downside+59.2%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$1.55 Trailing P/E Ratio42.93 Forward P/E Ratio41.15 P/E Growth2.16Net Income$541.50 million Net Margins16.95% Pretax Margin20.51% Return on Equity31.41% Return on Assets10.84% Debt Debt-to-Equity Ratio1.00 Current Ratio2.82 Quick Ratio2.48 Sales & Book Value Annual Sales$3.93 billion Price / Sales7.03 Cash Flow$2.07 per share Price / Cash Flow33.65 Book Value$5.35 per share Price / Book13.00Miscellaneous Outstanding Shares397,684,000Free Float399,525,000Market Cap$27.66 billion OptionableOptionable Beta1.18 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:DXCM) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.